161 related articles for article (PubMed ID: 15606615)
1. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome.
Gómez SA; Fernández GC; Camerano G; Dran G; Rosa FA; Barrionuevo P; Isturiz MA; Palermo MS
Clin Exp Immunol; 2005 Jan; 139(1):65-73. PubMed ID: 15606615
[TBL] [Abstract][Full Text] [Related]
2. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia.
Fernandez GC; Lopez MF; Gomez SA; Ramos MV; Bentancor LV; Fernandez-Brando RJ; Landoni VI; Dran GI; Meiss R; Isturiz MA; Palermo MS
Clin Exp Immunol; 2006 Oct; 146(1):76-84. PubMed ID: 16968401
[TBL] [Abstract][Full Text] [Related]
3. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
[TBL] [Abstract][Full Text] [Related]
4. Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome.
Gómez SA; Fernández GC; Vanzulli S; Dran G; Rubel C; Berki T; Isturiz MA; Palermo MS
Clin Exp Immunol; 2003 Feb; 131(2):217-24. PubMed ID: 12562380
[TBL] [Abstract][Full Text] [Related]
5. Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis.
Leech M; Hutchinson P; Holdsworth SR; Morand EF
Clin Exp Immunol; 1998 Jun; 112(3):383-8. PubMed ID: 9649205
[TBL] [Abstract][Full Text] [Related]
6. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.
Miceli S; Jure MA; de Saab OA; de Castillo MC; Rojas S; de Holgado AP; de Nader OM
Jpn J Infect Dis; 1999 Apr; 52(2):33-7. PubMed ID: 10816611
[TBL] [Abstract][Full Text] [Related]
7. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM
Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681
[TBL] [Abstract][Full Text] [Related]
8. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
9. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils.
Brigotti M; Carnicelli D; Arfilli V; Tamassia N; Borsetti F; Fabbri E; Tazzari PL; Ricci F; Pagliaro P; Spisni E; Cassatella MA
J Immunol; 2013 Nov; 191(9):4748-58. PubMed ID: 24068665
[TBL] [Abstract][Full Text] [Related]
10. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA
Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235
[TBL] [Abstract][Full Text] [Related]
11. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration.
Hurley BP; Thorpe CM; Acheson DW
Infect Immun; 2001 Oct; 69(10):6148-55. PubMed ID: 11553554
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
Guirro M; Piazza RM; de Souza RL; Guth BE
BMC Infect Dis; 2014 Jun; 14():320. PubMed ID: 24919599
[TBL] [Abstract][Full Text] [Related]
13. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.
Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M
Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967
[TBL] [Abstract][Full Text] [Related]
15. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
[TBL] [Abstract][Full Text] [Related]
16. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS).
Mejías MP; Hiriart Y; Lauché C; Fernández-Brando RJ; Pardo R; Bruballa A; Ramos MV; Goldbaum FA; Palermo MS; Zylberman V
Sci Rep; 2016 Apr; 6():24913. PubMed ID: 27118524
[TBL] [Abstract][Full Text] [Related]
17. Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Pineda GE; Rearte B; Todero MF; Bruballa AC; Bernal AM; Fernandez-Brando RJ; Isturiz MA; Zotta E; Alba-Soto CD; Palermo MS; Ramos MV
Clin Sci (Lond); 2021 Feb; 135(3):575-588. PubMed ID: 33496327
[TBL] [Abstract][Full Text] [Related]
18. Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome.
He X; Quiñones B; Loo MT; Loos S; Scavia G; Brigotti M; Levtchenko E; Monnens L
Acta Paediatr; 2015 Dec; 104(12):e564-8. PubMed ID: 26361237
[TBL] [Abstract][Full Text] [Related]
19. Defective neutrophil function in the autoimmune mouse strain MRL/lpr. Potential role of transforming growth factor-beta.
Gresham HD; Ray CJ; O'Sullivan FX
J Immunol; 1991 Jun; 146(11):3911-21. PubMed ID: 1674521
[TBL] [Abstract][Full Text] [Related]
20. Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome.
Fernández GC; Rubel C; Dran G; Gómez S; Isturiz MA; Palermo MS
Clin Immunol; 2000 Jun; 95(3):227-34. PubMed ID: 10866130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
